Efficacy and safety of apatinib and carrizumab (SHR1210) combined with transcatheter arterial chemoembolization (TACE) in the treatment of liver metastasis of gastrointestinal pancreatic neuroendocrine tumor (GEP-NET)

开始日期2021-09-01

申办/合作机构-

ChiCTR2100041865 / Recruiting临床4期IIT

Exploratory clinical study of Carrizumab combined with GC regimen in the treatment of advanced bladder cancer

开始日期2021-02-01

申办/合作机构-

ChiCTR2000040416 / Suspended临床4期IIT

A national wide, multicenter, prospective, real-world study of first-line treatment of advanced or metastatic non-small-cell lung cancer with carrizumab combined with pemetrexed plus platinum

开始日期2020-11-30

申办/合作机构

山东省肿瘤医院

100 项与 Carrizumab 相关的临床结果

登录后查看更多信息

100 项与 Carrizumab 相关的转化医学

登录后查看更多信息

100 项与 Carrizumab 相关的专利（医药）

登录后查看更多信息

项与 Carrizumab 相关的文献（医药）

2022-12-22·Case reports in hematology

PD-1 Checkpoint Blockade in Patients for Acute Myeloid Leukemia after HSCT Relapse Resulted in Severe GVHD and sHLH

作者: Zhou, Mi ; Kong, Lingjun ; Cheng, Shengqin ; Ling, Jing ; Du, Zhi zhuo ; Cao, Lan ; Hu, Shaoyan ; Xiao, Peifang

Treatment with immune checkpoint inhibitors (ICI) such as carrizumab leads to immune-mediated adverse effects including severe acute graft versus host disease (aGVHD) and secondary hemophagocytic syndrome (sHLH). Herein, we present two cases where aGVHD and sHLH developed after ICI administration, which was treated using methylprednisolone (MP). They developed high-grade fever complicated with liver dysfunction and diarrhea 1 day after ICI administration. Treatment with MP does not alleviate symptoms because of steroid resistance. Hyperbilirubinemia, rash with blisters, and watery diarrhea showed severe aGVHD. Hyperferritinemia, hypertriglyceridemia, and cytopenias suggested the diagnosis of HLH and met the criteria for sHLH diagnosis. They were thus administered intravenous high-dose MP, methotrexate (MTX), basiliximab, ruxolitinib, etc, which resolved these symptoms.

2022-01-20·Zhongguo fei ai za zhi = Chinese journal of lung cancer

[A Case Report of AFP-producing Primary Lung Squamous Cell Carcinoma  with Significant Therapeutic Effect].

Article

作者: Wang, Chen ; Wang, Yanbo ; Zhang, Wenjie ; Chen, Qing ; Guo, Qisen ; Yin, Juncheng

BACKGROUND:

Primary lung squamous carcinoma that produces alpha-fetoprotein (AFP) is rare and only four related cases have been reported so far. The specific reasons for elevated serum level of AFP and effective treatment regimens for AFP-producing lung squamous carcinoma are not clear. This paper reports the diagnosis and treatment of AFP-producing lung squamous carcinoma so as to provide some references for similar cases in clinical practice.

METHODS:

The diagnosis and treatment of an AFP-producing lung squamous carcinoma patient admitted to the Shandong Cancer Hospital on October 23, 2020 was retrospectively analyzed, and literatures were reviewed.

RESULTS:

A 52-year-old male patient was diagnosed as T4N3M0 stage, IIIc right upper lobe lung squamous cell carcinoma with mediastinal lymph node metastasis and multiple metastases in the lung. The main tumor marker was abnormally increased serum AFP. After the rapid progression of two lines chemotherapy, the patient was given anlotinib combined with carrizumab as third-line treatment. The efficacy evaluation reached to partial response (PR) and stable disease (SD) after 2 and 4 cycles of treatment, respectively. The treatment regimen was replaced with albumin paclitaxel plus carrizumab due to gastrointestinal bleeding after the fifth cycle. The patient's condition was under continuous control.

CONCLUSIONS:

The AFP-producing lung squamous carcinoma patient had a good response to anlotinib and immunotherapy in the case report, which may provide some guidances for the clinical practice and the research on AFP-producing lung squamous carcinoma.

100 项与 Carrizumab 相关的药物交易

登录后查看更多信息